You are here

Andrew Cherniack


Cherniack AD, Shen H, Walter V et al. Integrated Molecular Characterization of Uterine Carcinosarcoma Cancer. Cancer Cell. 2017; 31(3): 411-423.

Zheng S, Cherniack AD, Dewal N et al. Comprehensive pan-genomic characterization of adrenocortical carcinoma. Cancer Cell. 2016;29(5):723-736.

Cancer Genome Atlas Research Network. Comprehensive, integrative genomic analysis of diffuse lower-grade gliomas. N Engl J Med. 2015;372(26):2481–2498.

Hoadley KA, Yau C, Wolf DM, Cherniack AD et al. Multiplatform analysis of 12 cancer types reveals molecular classification within and across tissues of origin. Cell. 2014;158(4):929-44.

Andrew Cherniack, Ph.D.

Andrew Cherniack is a group leader in the Cancer Program at the Broad Institute of MIT and Harvard as a member of the Meyerson Lab. He led the Broad Institute’s effort to analyze somatic DNA copy number alterations for The Cancer Genome Atlas (TCGA) and is now co-principal investigator of the Broad Institute’s copy number Genome Data Analysis Center for the National Cancer Institute’s Genomic Data Analysis Network (GDAN). He also leads the oncoming effort to identify new cancer therapeutic targets for the partnership with Bayer.

Prior to joining the Broad Institute in 2010, Cherniack worked in both academia and industry, with a 9-year tenure at the Abbott Bioresearch Center following a similar time period in the Program in Molecular Medicine at UMass Medical School, where he was a postdoctoral researcher and a research assistant professor.

Cherniack holds a Ph.D. in molecular genetics from Ohio State University and a B.A. in biology from the University of Pennsylvania.

September 2017